NanOlogy Announces an Abstract Has Been Accepted for Presentation at the IASLC North America Conference on Lung Cancer

FORT WORTH (November 20, 2023) — NanOlogy LLC, a clinical-stage oncology company, announced today that an abstract reporting interim results from its lung cancer trial has been accepted for poster presentation at the IASLC North America Conference on Lung Cancer (NACLC) being held December 1-3, 2023, at the Chicago Marriott Downtown Magnificent Mile.

The abstract (PP01.111) entitled: “Phase 2a Intratumoral Large Surface Area Microparticle Paclitaxel in Stage 3/4 Lung Cancer” will be presented by Hiren Mehta, MD (University of Florida Health) during poster sessions on Saturday, December 2nd, and Sunday, December 3rd.

A press release summarizing presentation data will be issued following the conference.

The IASLC North America Conference on Lung Cancer (NACLC)

About NanOlogy

NanOlogy, LLC ( is a private clinical-stage oncology company formed in 2015 to improve the treatment of solid tumors with investigational drugs optimized for intratumoral delivery by a proprietary particle engineering technology platform. NanOlogy clinical programs have advanced investigational drugs in multiple solid tumors including pancreas, lung, bladder, peritoneal, ovarian, prostate, and dermal cancers. The investigational drugs are covered by composition of matter patents issued in the US (9,814,685, 10,507,195, 10,993,927, and 11,123,322), and other major jurisdictions worldwide, including Canada, Europe, Japan, China, South Korea, Australia, and India valid through June 2036. The composition patents form the foundation of an extensive intellectual property portfolio of over 130 issued patents protecting NanOlogy investigational drugs, formulations, methods, and technology.

Media Contact
Dan Eramian
Opus Biotech Communications